"HCC is a major challenge due to greater recurrence rates and variable treatment responses. TACE is widely used, but its success relies on accurate follow-up imaging. CT Triphasic Liver Imaging plays a vital role in assessing treatment response, guiding clinical decisions, and improving patient outcomes. The purpose of this study is to investigate the relationship between response of treatment, gender, age, and the cause of HCC. The purpose of the study is to evaluate how well TACE (trans-arterial chemoembolization) works for patients with HCC.

This will be a retrospective observational study aimed at evaluating the effectiveness of Trans-Arterial Chemo-Embolization in the management of Hepatocellular Carcinoma (HCC) using follow-up CT Triphasic Liver imaging. Patient records and imaging data from past cases will be reviewed to assess post- treatment tumor response and progression.

Inclusion Criteria:

• Both Male and Female.
• Patients diagnosed with HCC who underwent TACE.
• Patients with no portal vein tumor thrombus (PVTT) or no extra Extrahepatic Metastases at the time of initial TACE treatment.
• Patients who underwent TACE within last your years from the study start date.

Exclusion Criteria:

• Patients with incomplete or missing medical records and imaging studies.
• Patients with a history of severe comorbidities that might interfere with treatment response evaluation
• Patients who were contraindicated for CT scans at the time of follow-up.
• Patients that are contradicted with CT scan.
• Patient who underwent TACE more than four years before the study period.

his will be a retrospective observational study aimed at evaluating the effectiveness of Trans-Arterial Chemo-Embolization in the management of Hepatocellular Carcinoma (HCC) using follow-up CT Triphasic Liver imaging. Patient records and imaging data from past cases will be reviewed to assess post- treatment tumor response and progression.